Lantheus and GE Healthcare sign license agreement for flurpiridaz F 18

Lantheus Holdings and GE Healthcare signed a definitive license agreement for the continued Phase III development and worldwide commercialization of flurpiridaz F 18, an investigational PET MPI agent. GE Healthcare will lead and fund development and have exclusive worldwide commercialization rights.

“With our definitive agreement for flurpiridaz F 18 in place, we look forward to collaborating with GE Healthcare to complete the development and commercialization efforts to bring this novel PET cardiac imaging agent to market.”businesswire.com

• 1 source
• businesswire.comLantheus and GE Healthcare Announce the Signing of a Definitive License Agreement for Worldwide Development and Commercialization of Flurpiridaz F 18Apr 25, 2017

Summarized from public sources; check the original articles before acting on it.